Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022

Whitehawk Therapeutics, Inc.

FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.
Cash and equivalents $149M as of Dec 31, 2021, expected to fund operations into 2024.
Q4 2021 net loss $16M vs net income $7.8M in Q4 2020; full year net loss $110.7M.
Phase 2 PRECISION 1 trial (TSC1/TSC2 alterations) open; initial data expected H1 2023.
Operating expenses Q4 $16.9M, up from $5.7M; G&A increased due to commercial buildout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.